CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Curis Doses First Five Patients in TakeAim CLL Study

Trial StartPositive
AI Analysis

Summary

Curis has dosed the first five patients in the TakeAim CLL study, marking the initiation of patient enrollment in this clinical trial for chronic lymphocytic leukemia treatment.

Clinical Trial Data

Patients

5

Importance:3/10
Sentiment:
0.30
clinical trialCLLpatient enrollmentTakeAim study
Related Companies

Read the original article

Published by yahoo_finance on July 30, 2026 12:00 PM

Read Original